BRIEF-Tryngolza (Olezarsen) Approved In U.S. As First-Ever Treatment For Adults Living With Familial Chylomicronemia Syndrome As An Adjunct To Diet

Reuters

2024/12/20

Dec 19 (Reuters) - Ionis Pharmaceuticals Inc :

* TRYNGOLZA™ (OLEZARSEN) APPROVED IN U.S. AS FIRST-EVER TREATMENT FOR ADULTS LIVING WITH FAMILIAL CHYLOMICRONEMIA SYNDROME AS AN ADJUNCT TO DIET

* IONIS PHARMACEUTICALS INC - TRYNGOLZA TO BE AVAILABLE IN U.S. BEFORE YEAR END

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492435000"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492435000\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492435000?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492435000","market":"us","top_or_hot":-1,"title":"BRIEF-Tryngolza (Olezarsen) Approved In U.S. As First-Ever Treatment For Adults Living With Familial Chylomicronemia Syndrome As An Adjunct To Diet","media":"Reuters","content":"<html><body><p>Dec 19 (Reuters) - Ionis Pharmaceuticals Inc   :</p><p>   * TRYNGOLZA™ (OLEZARSEN) APPROVED IN U.S. AS FIRST-EVER TREATMENT FOR ADULTS LIVING WITH FAMILIAL CHYLOMICRONEMIA SYNDROME AS AN ADJUNCT TO DIET</p><p>   * IONIS PHARMACEUTICALS INC - TRYNGOLZA TO BE AVAILABLE IN U.S. BEFORE YEAR END</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tryngolza (Olezarsen) Approved In U.S. As First-Ever Treatment For Adults Living With Familial Chylomicronemia Syndrome As An Adjunct To Diet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tryngolza (Olezarsen) Approved In U.S. As First-Ever Treatment For Adults Living With Familial Chylomicronemia Syndrome As An Adjunct To Diet\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-12-20 07:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>Dec 19 (Reuters) - Ionis Pharmaceuticals Inc   :</p><p>   * TRYNGOLZA™ (OLEZARSEN) APPROVED IN U.S. AS FIRST-EVER TREATMENT FOR ADULTS LIVING WITH FAMILIAL CHYLOMICRONEMIA SYNDROME AS AN ADJUNCT TO DIET</p><p>   * IONIS PHARMACEUTICALS INC - TRYNGOLZA TO BE AVAILABLE IN U.S. BEFORE YEAR END</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2492435000","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492435000","pubTimestamp":1734651028,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 19  - Ionis Pharmaceuticals Inc   :   * TRYNGOLZA  APPROVED IN U.S. AS FIRST-EVER TREATMENT FOR ADULTS LIVING WITH FAMILIAL CHYLOMICRONEMIA SYNDROME AS AN ADJUNCT TO DIET   * IONIS PHARMACEUTICALS INC - TRYNGOLZA TO BE AVAILABLE IN U.S. BEFORE YEAR ENDSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc","BK4139":"生物科技"},"translate_title":"简介-Tryngolza(Olezarsen)在美国首次被批准作为饮食辅助治疗患有家族性乳糜微粒血症综合征的成年人","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"Dec 19 (Reuters) - Ionis Pharmaceuticals Inc   :   * TRYNGOLZA™ (OLEZARSEN) APPROVED IN U.S. AS FIRST-EVER TREATMENT FOR ADULTS LIVING WITH FAMILIAL CHYLOMICRONEMIA SYNDROME AS AN ADJUNCT TO DIET   * IONIS PHARMACEUTICALS INC - TRYNGOLZA TO BE AVAILABLE IN U.S. BEFORE YEAR ENDSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}